Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Charles Ebert

Otolaryngology Chapel Hill, NC Medical Doctor

NPI 1114147022 CMS profile 394696

101 Manning Dr, Rm 1107G W Wing, Chapel Hill, NC 27514

Open in the dashboard

General payments

$56,983

107 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Charles Ebert of Chapel Hill, NC is reported in the CMS Open Payments database as having received $56,983 across 107 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $523 8
2024 General $2,399 17
2023 General $11,844 24
2022 General $9,694 21
2021 General $326 4
2020 General $15,203 7
2019 General $16,994 26

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Charles Ebert
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Charles Ebert were reported at $523. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Charles Ebert Otolaryngology median Middle half National median
2019 $16,994 $194 $82–$512 $163
2020 $15,203 $118 $42–$280 $114
2021 $326 $167 $63–$444 $132
2022 $9,694 $216 $84–$545 $149
2023 $11,844 $235 $93–$588 $160
2024 $2,399 $280 $111–$699 $164
2025 $523 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Acclarent, Inc $42,658 64 payments
  2. Medtronic USA, Inc. $6,351 8 payments
  3. Medical Device Business Services, Inc. $3,782 5 payments
  4. Integra LifeSciences Corporation $2,308 18 payments
  5. 3-D Matrix, Inc. $1,121 2 payments
  6. Neurent Medical Limited $312 2 payments
  7. Stryker Corporation $174 2 payments
  8. GlaxoSmithKline, LLC. $93 1 payment
  9. Aerin Medical Inc. $64 2 payments
  10. ALK-Abello, Inc $62 1 payment
  11. Other $59 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $47,120 19 payments
  2. Food and Beverage $7,286 77 payments
  3. Travel and Lodging $2,577 11 payments
Products named General payments · program years 2019–2025
  1. ACCLARENT Balloon Inflation Device Rhinology Laryngology $19,636 9 payments
  2. ACCLARENT AERA EUSTACHIAN TUBE BALLOON DILATION SYSTEM $15,010 3 payments
  3. ACCLARENT Balloon Inflation Device Rhinology Laryngology $12,087 11 payments
  4. TruDi Nav Suction $11,988 10 payments
  5. StealthStation $6,291 6 payments
  6. TruDi $4,763 9 payments
  7. SpinPlus Navigation $4,246 2 payments
  8. TruDi Navigation System $3,306 5 payments
  9. ACCLARENT AERA $2,260 17 payments
  10. INSPIRA AIR $2,123 16 payments
  11. Other $7,046 78 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

378

Median for Otolaryngology: 297

Drug cost

$9,622

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mometasone Furoate Generic 33 $3,425
Fluticasone Propionate Generic 153 $2,966
Ipratropium Bromide Generic 86 $2,413
Mupirocin Generic 33 $228
Azelastine Hcl Generic 11 $223
Doxycycline Hyclate Generic 18 $187
Chlorhexidine Gluconate Generic 12 $89
Montelukast Sodium Generic 19 $46
Omeprazole Generic 13 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$63,727

Medicare's payments for the services billed

Medicare patients

170

Average age 73

Services billed

508

95 women, 75 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 72%
Arthritis 55%
Depression 27%
Diabetes 24%
Chronic kidney disease 22%
Ischemic heart disease 21%
Osteoporosis 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

107 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record